Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Enzomenib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Sumitomo Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Sumitomo Pharma America Enters into a CRADA with the National Cancer Institute
Details : The collaboration aims to evaluate DSP-5336 (enzomenib), an oral, small molecule designed to inhibit the menin and KMT2A protein interaction present in certain difficult to treat cancers.
Product Name : DSP-5336
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 14, 2025
Lead Product(s) : Enzomenib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Sumitomo Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Eureka Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the licensing agreement, Eureka will develop and commercialize a novel antibody targeting MSLN, a potentially transformative T-cell therapy for solid tumors, in combination with ARTEMIS® T-cell receptor platform.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 14, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Eureka Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : NAV-001
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Navrogen
Deal Size : Undisclosed
Deal Type : Agreement
Details : NAV-001 targets tumors expressing the cancer antigen mesothelin, a cell surface protein over-expressed on various malignancies, including breast, colon, lung and mesothelioma cancers.
Product Name : NAV-001
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
July 11, 2022
Lead Product(s) : NAV-001
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Navrogen
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Arsenic Trioxide,Tretinoin
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Drug Combination Helps Children with Acute Promyelocytic Leukemia Avoid Conventional Chemotherapy
Details : A clinical trial has found that the combination of all-trans retinoic acid, which is a metabolite of vitamin A, and arsenic trioxide is highly effective in children with standard- and high-risk acute promyelocytic leukemia, or APL.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
December 11, 2021
Lead Product(s) : Arsenic Trioxide,Tretinoin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pelcitoclax,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Ascentage Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Ascentage Pharma Establishes Cooperative R&D Agreement (CRADA) with the NIH
Details : Ascentage Pharma and the NCI will collaborate on a series of clinical trials to evaluate the safety and efficacy of pelcitoclax, Ascentage Pharma's dual inhibitor of BCL-2 and BCL-xL proteins, in solid tumors based upon encouraging anti-tumor activity.
Product Name : APG-1252
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 19, 2021
Lead Product(s) : Pelcitoclax,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Ascentage Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : ST101
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Sapience Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : ST101, a first-in-class peptide antagonist of C/EBPβ, will be investigated for its impact on primary and metastatic cancer and the tumor microenvironment, leveraging NCI's expertise in C/EBP biology and genetic mouse models
Product Name : ST101
Product Type : Peptide
Upfront Cash : Undisclosed
May 27, 2021
Lead Product(s) : ST101
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Sapience Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Abiraterone Decanoate
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Propella Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Details : Under this new partnership, Propella and NCI will conduct a multi-center clinical trial to evaluate abiraterone decanoate, as a new therapy for metastatic prostate cancer.
Product Name : PRL-02
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 23, 2021
Lead Product(s) : Abiraterone Decanoate
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Propella Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : PDS0103
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : PDS Biotechnology
Deal Size : Undisclosed
Deal Type : Agreement
Details : This expansion adds to the NCI’s ongoing evaluation of PDS0101 in combination with two separate immune-modulating agents, NHS-IL12 and M7824 to treat advanced HPV-associated cancers.
Product Name : PDS0103
Product Type : Vaccine
Upfront Cash : Undisclosed
April 29, 2020
Lead Product(s) : PDS0103
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : PDS Biotechnology
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : ELI-002
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Elicio Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : This collaborative study investigates the mechanism of action of ELI-002 in mice that have key human HLA genes important for immune response.
Product Name : ELI-002
Product Type : Vaccine
Upfront Cash : Undisclosed
April 16, 2020
Lead Product(s) : ELI-002
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Elicio Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
LIDDS: Second patient treated in the Phase I study, NZ-DTX-001
Details : The NZ-DTX-001 study is a multi-center study including Karolinska University Hospital in Sweden, Herlev Hospital in Denmark, Kaunas University Hospital and Vilnius National Cancer Institute.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
February 19, 2020